Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
29.65 USD | +11.84% | +9.70% | -12.37% |
05:09pm | Needham Adjusts Price Target on Pacira BioSciences to $43 From $45, Keeps Buy Rating | MT |
May. 07 | Transcript : Pacira BioSciences, Inc., Q1 2024 Earnings Call, May 07, 2024 |
Financials (USD)
Sales 2024 * | 693M | Sales 2025 * | 761M | Capitalization | 1.23B |
---|---|---|---|---|---|
Net income 2024 * | 59M | Net income 2025 * | 92M | EV / Sales 2024 * | 1.89 x |
Net Debt 2024 * | 78.88M | Net cash position 2025 * | 135M | EV / Sales 2025 * | 1.44 x |
P/E ratio 2024 * |
22.2
x | P/E ratio 2025 * |
13.7
x | Employees | 712 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.74% |
Latest transcript on Pacira BioSciences, Inc.
1 day | +11.52% | ||
1 week | +9.70% | ||
Current month | +12.63% | ||
1 month | +3.81% | ||
3 months | +6.73% | ||
6 months | -1.19% | ||
Current year | -12.37% |
Managers | Title | Age | Since |
---|---|---|---|
Frank Lee
CEO | Chief Executive Officer | 56 | Jan. 01 |
Charles Reinhart
DFI | Director of Finance/CFO | 63 | 11-10-31 |
Jonathan Slonin
CTO | Chief Tech/Sci/R&D Officer | 49 | 21-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Gary Pace
BRD | Director/Board Member | 76 | 08-05-31 |
Paul Hastings
CHM | Chairman | 64 | 11-06-01 |
Andreas Wicki
BRD | Director/Board Member | 64 | 06-11-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.24% | 0 M€ | -3.66% | - | |
0.18% | 0 M€ | +2.62% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-08 | 29.65 | +11.84% | 1 939 962 |
24-05-07 | 26.51 | +0.04% | 734,470 |
24-05-06 | 26.5 | -2.61% | 733,744 |
24-05-03 | 27.21 | -0.40% | 247,316 |
24-05-02 | 27.32 | +1.37% | 340,710 |
Delayed Quote Nasdaq, May 08, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.37% | 1.23B | |
+33.09% | 700B | |
-4.97% | 358B | |
+18.88% | 330B | |
+3.50% | 287B | |
+15.70% | 236B | |
+6.68% | 202B | |
-9.08% | 197B | |
+6.71% | 161B | |
-1.82% | 157B |
- Stock Market
- Equities
- PCRX Stock